PubRank

Bartosz Chmielowski

Author PubWeight™ 78.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
2 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
3 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
4 Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010 5.57
5 KIT as a therapeutic target in metastatic melanoma. JAMA 2011 3.49
6 Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res 2009 3.01
7 Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012 2.27
8 The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010 2.02
9 Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013 1.99
10 Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011 1.89
11 Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009 1.81
12 Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med 2015 1.75
13 Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov 2013 1.68
14 The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol 2014 1.45
15 CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011 1.42
16 Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 2012 1.18
17 Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010 1.13
18 Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010 1.09
19 Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res 2011 1.04
20 Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014 1.01
21 Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas. J Thorac Oncol 2012 0.94
22 Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med 2010 0.87
23 Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013 0.85
24 Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One 2013 0.83
25 CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother 2010 0.80
26 Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma 2013 0.79
27 Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2017 0.78
28 Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol 2009 0.76
29 The specific T-cell response to antigenic peptides is influenced by bystander peptides. Cell Mol Biol Lett 2006 0.75
30 Predictors of Local Recurrence in Patients With Myxofibrosarcoma. Am J Clin Oncol 2017 0.75